Fundraising FoxAziyo Biologics
NASDAQ: ELUTSilver Spring, US · Founded 2015 · Delaware corporation · 2 known investors
Find your way into Aziyo Biologics
Aziyo Biologics (operating as Elutia) develops drug-eluting biomatrix products that combine biologic scaffolds with localized antibiotic delivery to reduce surgical complications in reconstructive and soft tissue repair procedures. The company commercializes biologic matrix products like SimpliDerm for soft tissue reconstruction and cardiovascular repair products, while advancing its next-generation NXT-41 and NXT-41x platforms for broader surgical applications.
Founders & leadership
ML
Michelle LeRoux WilliamsExecutive
JD
Jeffrey D HametExecutive
LD
Lode DebrabandereExecutive
CR
C. Randal MillsPresident, Chief Executive Officer, Director
Board
WM
William Matthew ZugaBoard director
KR
CR
Charles Randal MillsBoard director
Investors · 2
Also in the syndicate · 1
SWK Holdings Corporation
Reported raises · per SEC filings
Form D private placements$54.6M disclosed across 6 of 7 rounds · 2017–2023
▶$10.5MraisedOct 2023 · 12 investors · BiotechnologyRule 506(b)
▶$10.5MraisedOct 2023 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- W. Matthew ZugaDirector
- C. Randal MillsExecutive Officer, Director
- Michelle LeRoux WilliamsExecutive Officer
- Matthew FergusonExecutive Officer
- Jeffrey HametExecutive Officer
- Kevin RakinDirector
- Maybelle JordanDirector
- David ColpmanDirector
- Brigid A. MakesDirector
- Offering amount
- $10.5M
- Amount sold
- $10.5M
- Sales commissions
- $598.5K
- Placement agents
- Lake Street Capital Markets, LLC
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14MraisedDec 2021 · 15 investors · BiotechnologyRule 506(b)
▶$14MraisedDec 2021 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brigid A. MakesDirector
- Ronald LloydExecutive Officer, Director
- Matthew FergusonExecutive Officer
- Maybelle JordanDirector
- Kevin RakinDirector
- W. Matthew ZugaDirector
- C. Randal Mills. Ph.D.Director
- Jeffrey HametExecutive Officer
- Offering amount
- $14M
- Amount sold
- $14M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedSep 2020 · 5 investors · BiotechnologyRule 506(b)
▶$5MraisedSep 2020 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles Randal MillsDirector
- Jeffrey D HametExecutive Officer
- Steven HochbergDirector
- William Matthew ZugaDirector
- Ronald LloydExecutive Officer, Director
- Kevin RakinDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$3.1MraisedDec 2019 · 5 investors · BiotechnologyRule 506(b)
▶$3.1MraisedDec 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven HotchbergDirector
- Kevin RakinDirector
- Charles Randal MillsDirector
- Jeffrey D HametExecutive Officer
- Ronald LloydExecutive Officer
- William Matthew ZugaDirector
- Offering amount
- $3.5M
- Amount sold
- $3.1M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$10MraisedAug 2018 · 7 investors · BiotechnologyRule 506(b)
▶$10MraisedAug 2018 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William HochbergDirector
- Michelle LeRoux WilliamsExecutive Officer
- Kevin RakinDirector
- Charles Randal MillsDirector
- Ronald LloydExecutive Officer, Director
- Jeffrey D HametExecutive Officer
- William Matthew ZugaDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$12MraisedJun 2017 · 3 investors · BiotechnologyRule 506(b)
▶$12MraisedJun 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles Randal MillsDirector
- Michelle LeRoux WilliamsExecutive Officer
- William Matthew ZugaDirector
- Jeffrey D HametExecutive Officer
- Lode DebrabandereExecutive Officer, Director
- Kevin RakinDirector
- Offering amount
- $12M
- Amount sold
- $12M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$173.8Mvaluation at IPOOct 2020 · $17.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Frequently asked questions
- What does Aziyo Biologics do?
- Aziyo Biologics (operating as Elutia) develops drug-eluting biomatrix products that combine biologic scaffolds with localized antibiotic delivery to reduce surgical complications in reconstructive and soft tissue repair procedures. The company commercializes biologic matrix products like SimpliDerm for soft tissue reconstruction and cardiovascular repair products, while advancing its next-generation NXT-41 and NXT-41x platforms for broader surgical applications.
- Who are Aziyo Biologics's investors?
- Aziyo Biologics's investors include HighCape Capital.
- How much funding has Aziyo Biologics raised?
- Aziyo Biologics has disclosed $54.6M raised across 6 of its 7 known rounds.
- Where is Aziyo Biologics headquartered?
- Aziyo Biologics is headquartered in Silver Spring, US.